R3I1 Stock Overview
Advanced Oncotherapy plc, together with its subsidiaries, engages in the designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Advanced Oncotherapy plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.021 |
| 52 Week High | UK£0.27 |
| 52 Week Low | UK£0.0085 |
| Beta | 0.063 |
| 1 Month Change | 0% |
| 3 Month Change | -14.00% |
| 1 Year Change | -91.92% |
| 3 Year Change | -93.20% |
| 5 Year Change | -95.40% |
| Change since IPO | -96.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| R3I1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.6% | 0.3% |
| 1Y | -91.9% | -9.1% | 6.9% |
Return vs Industry: R3I1 underperformed the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: R3I1 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| R3I1 volatility | |
|---|---|
| R3I1 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: R3I1's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine R3I1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 174 | Nicolas Serandour | www.avoplc.com |
Advanced Oncotherapy plc, together with its subsidiaries, engages in the designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties.
Advanced Oncotherapy plc Fundamentals Summary
| R3I1 fundamental statistics | |
|---|---|
| Market cap | €10.95m |
| Earnings (TTM) | -€37.59m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs R3I1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R3I1 income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£32.60m |
| Earnings | -UK£32.60m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 39.6% |
How did R3I1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/25 23:16 |
| End of Day Share Price | 2023/06/29 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Advanced Oncotherapy plc is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Redhead | goetzpartners securities Limited |
| Jon Levinson | Growth Equities & Company Research |
| Yingheng Chen | Hardman & Co. |